Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:31:21 29/06/2024 am IST			5-day change	1st Jan Change
27.98 ^USD	+0.65%		+0.87%	-2.81%

28/06	Pfizer: CHMP recommends new Covid vaccine	CF
28/06	Would you like some more inflation?

China says talks to include Paxlovid in state health insurance fail

January 08, 2023 at 04:09 pm IST

BEIJING (Reuters) - China's Health Security Administration said on Sunday that talks to include Pfizer's Paxlovid in the latest drug list for basic state health insurance did not succeed.

The talks fell through was due to Pfizer's high quotation for Paxlovid. Pfizer did not immeditately respond to a request to comment.

(Reporting by Brenda Goh and Yingzhi Yang; Editing by Raissa Kasolowsky)

Latest news about Pfizer, Inc.

Pfizer: CHMP recommends new Covid vaccine	28/06	CF
Would you like some more inflation?	28/06
EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older	28/06	RE
Pfizer Inc.(NYSE:PFE) dropped from Russell Top 50 Index	28/06	CI
Pfizer, BioNTech Get Positive Committee Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in European Union	27/06	MT
Pfizer, BioNTech Get Positive CHMP Opinion for New Covid-19 Vaccine	27/06	DJ
Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer	27/06	CI
GSK Shares Slump After CDC Narrows Age Recommendation for RSV Shots	27/06	DJ
CDC Updates RSV Shot Recommendation Among the Elderly; Vaccine Makers Mixed Pre-Bell	27/06	MT
Nervy trade in London before US data	27/06	AN
Pfizer Keeps Q3 Dividend at $0.42 a Share, Payable Sept. 3 to Holders of Record July 26	27/06	MT
Pfizer Inc. Declares Third-Quarter 2024 Dividend on the Company?s Common Stock, Payable on September 3, 2024	27/06	CI
Moderna Shares Fall as RSV Shot Efficacy Lags Behind Rivals' Vaccines, CDC Data Shows	27/06	MT
CDC advisers narrow age recommendation for RSV shots in US	27/06	RE
US CDC Advisers Recommend RSV Vaccine For Adults Aged 60 Years Of Age And Above	27/06	RE
Moderna RSV Shot Efficacy Lower Than Rivals' Vaccines, CDC Data Shows	27/06	MT
Moderna RSV Shot Efficacy Lower Than Rivals', CDC Data Shows; Shares Down 9.5%	27/06	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes	26/06	CI
CVRx, Inc. Announces Appointment of Robert Allen John as Chief Revenue Officer, Effective June 27, 2024	25/06	CI
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06	RE
Sarepta surges as investors cheer expanded use of gene therapy	21/06	RE

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 09:28 pm IST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 01, 2023 at 02:20 am IST

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.98 USD

Average target price

31.92 USD

Spread / Average Target

+14.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-2.81%	16TCr
ELI LILLY AND COMPANY	+55.32%	82TCr
NOVO NORDISK A/S	+44.05%	64TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	31TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
ROCHE HOLDING AG	+2.04%	22TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

China says talks to include Paxlovid in state health insurance fail

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals